Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: Lead candidate vepdegestrant for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102 for the treatment of patients with neurodegenerative disorders, and ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas.
In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC® androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.
#TeamArvinas is made up of approximately 450 passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.
For more information, please visit www.arvinas.com.
Position Summary
The Senior Director of Commercial Learning & Development is responsible for identifying, developing and implementing Arvinas’ US commercial team’s training needs, in collaboration with the Marketing and Sales teams. This position requires the ability to seamlessly collaborate with our alliance partner and deliver on strategies to successfully launch vepdegestrant in breast cancer and maximize its commercial value compliantly. This includes establishing learning and development capabilities for Arvinas’ first commercial field team and successfully pulling through promotional tactics to drive awareness, trial and appropriate usage of vepdegestrant. The Senior Director of Commercial Learning & Development is an exciting opportunity for a high-performing individual who could work alongside commercial peers from Arvinas and our alliance partner in a collaborative and compliant manner that ensures a successful launch.
This position reports to the Executive Director of Breast Cancer Marketing and can work remotely from a location within the U.S.
Principal Responsibilities
Key responsibilities of this role include, but are not limited to:
Qualifications
Education
#LI-Remote
Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com
Arvinas is an Equal Opportunity Employer
BillionToOne
Tempus
Sinch
NoGigiddy
Veeva Systems